These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28722840)

  • 21. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report.
    Draugalis JR; Coons SJ
    Clin Ther; 1994; 16(3):523-37; discussion 522. PubMed ID: 7923318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 27. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.
    Bodrogi J; Kaló Z
    Br J Pharmacol; 2010 Apr; 159(7):1367-73. PubMed ID: 20132213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics and immunotherapy.
    Berto P
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():12-6. PubMed ID: 18924461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds.
    Jönsson B
    Pharmacoeconomics; 2004; 22 Suppl 4():5-10. PubMed ID: 15876007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?
    Ikegami N; Drummond M; Fukuhara S; Nishimura S; Torrance GW; Schubert F
    Pharmacoeconomics; 2002; 20 Suppl 2():1-7. PubMed ID: 12238943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PharmacoEconomics. Foreword.
    Milne CP
    Pharmacoeconomics; 2006 Dec; 24 Suppl 2():1-3. PubMed ID: 23389483
    [No Abstract]   [Full Text] [Related]  

  • 38. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario?
    Preziosi P
    Nat Rev Drug Discov; 2004 Jun; 3(6):521-6. PubMed ID: 15173841
    [No Abstract]   [Full Text] [Related]  

  • 39. The emerging government requirement for economic evaluation of pharmaceuticals.
    Drummond M
    Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The French medecine pricing committee and the medicine economic policy: Rules and competences].
    Giorgi D
    Ann Pharm Fr; 2017 Sep; 75(5):359-372. PubMed ID: 28522031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.